AstraZeneca Covid Vax Linked to Another Rare Fatal Blood Clotting Disorder

sanstuti nath sanstuti nath | 05-17 00:00

British-Swedish pharma giant AstraZeneca’s Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) — a rare but fatal blood clotting disorder, claimed researchers on Thursday.

While not new, VITT emerged as a new disease following adenovirus vector-based Oxford-AstraZeneca vaccine — sold as Covishield in India and Vaxzevria in Europe — at the height of the Covid pandemic in 2021.

“An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4)” was found as the reason for VITT.

In separate research in 2023, scientists from Canada, North America, Germany and Italy described a virtually identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.

Now in a new research, Flinders University in Australia and other international experts found that the PF4 antibodies in both adenovirus infection-associated VITT and classic adenoviral vector VITT share identical molecular fingerprints or signatures.

“Indeed, the pathways of lethal antibody production in these disorders must be virtually identical and have similar genetic risk factors,” said Professor Tom Gordon from Flinders

The researcher noted that the “findings have the important clinical implication that lessons learned from VITT are applicable to rare cases of blood clotting after adenovirus (a common cold) infections, as well as having implications for vaccine development”.

The same team had in a 2022 study “cracked the molecular code of the PF4 antibody and identified a genetic risk factor”.

Their new findings, published in the New England Journal of Medicine, also have important implications for improving vaccine safety.

The research comes after AstraZeneca “accepted, in a legal document submitted to the High Court in February, that its Covid vaccine ‘can, in very rare cases, cause Thrombotic Thrombocytopenic Syndrome (TTS)’.”

TTS is a rare side effect that can cause people to have blood clots and a low blood platelet count. It has been linked to the death of at least 81 people in the UK as well as hundreds of serious injuries.

The company has also voluntarily withdrawn “marketing authorisation” of its Covid vaccine from Europe and other global markets.

Explore in-depth coverage of Lok Sabha Election 2024 Schedule, Voter Turnout, Upcoming Phase And Much More At News18 Website

(This story has not been edited by News18 staff and is published from a syndicated news agency feed - IANS)
About the Author
Sanstuti Nath
With around five years of experience on the desk as well as reporting, Sanstuti Nath is a Senior Sub Editor at News18.com. She writes on Indian politi...Read More

Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.


ALSO READ

Hyundai Motor India lists with record IPO, commits to Indian market with new tech and EV plans

As part of its effort to introduce clean mobility solutions for Indian buyers, Hyundai will launch f...

auto | 7 hours ago

Skoda Auto Volkswagen India plants over 7 lakh trees in Maharashtra for ecological restoration

Additionally, SAVWIPL has installed 18.5 MWp of rooftop solar power at its Chakan facility, which of...

auto | 7 hours ago

Mega Corporation launches Lendingo to enhance EV financing solutions

Mega Corporation on Monday announced the launch of a new division, Lendingo. Mega Corporation on Mon...

auto | 7 hours ago

GreenLine accelerates decarbonisation efforts with 1,000 LNG trucks by March 2025

The government in a recent draft policy proposed to convert a third of long-haul trucks into LNG pow...

auto | 7 hours ago

Remsons Industries acquires 51% stake in BEE Lighting to enhance automotive lighting solutions

Established in 2006, BEE Lighting specialises in automotive headlamps, rear lamps, and various exter...

auto | 7 hours ago

EV Recharge partners with ZEVO for mobile EV charging solutions

EV Recharge’s technology can charge vehicles from 0% to 80% in just 20 minutes, a significant improv...

auto | 7 hours ago